Condition: Glomerulonephritis Rapidly Progressive · Sponsor: Alentis Therapeutics AG
The goal of this clinical trial is to learn if a new drug that might help protect and preserve kidney function in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a type of autoimmune disease where the body's own immune system attacks itself, and in the case of AAV the body attacks its own small blood vessels. There are many small blood vessels in the kidneys meaning the kidneys are commonly affected in AAV. The main questions it aims to answer are: * Is the new drug well tolerated and safe? * Can the new drug protect and preserve kidney functions when is added to standard therapy? Researchers will compare the following groups to see how the new drug is tolerated and what effect to preserve kidney tissue has: * Group A: Standard treatment + ALE.F02 low dose infusions * Group B: Standard treatment + ALE.F02 high dose infusions * Group C: Standard treatment + ALE.F02 maximum dose infusions * Group D: Standard treatment + placebo infusions (inactive substance) The Treatment period will consist of 24 weeks beginning on Day 1, during which time participants will receive 13 infusions of the study medicine, along with standard therapy for kidney inflammation due to AAV. During the treatment period, participants will have the following assessments: * A brief physical examination focusing on their skin any pre-existing medical conditions that you have. * Collection of blood and urine samples for routine safety tests and to assess renal function. * C…
This description comes directly from the study's public registry record.
Mohamed Benabed · +41 78 266 19 91 · mohamed.benabed@alentis.ch
Always discuss trial participation with your own doctor first.
| Vseobecna fakultni nemocnice v Praze | Prague, Czechia | Recruiting |
| Institut klinicke a experimentalni mediciny | Prague, Czechia | Recruiting |
| Aalborg University Hospital | Aalborg, Denmark | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Odense University Hospital | Odense, Denmark | Recruiting |
| Centre Hospitalier Boulogne sur Mer | Boulogne-sur-Mer, Cedex, France | Recruiting |
| CHU Bordeaux - Hopital Pellegrin | Bordeaux, France | Recruiting |
| CHRU de Brest - Hopital de la Cavale Blanche | Brest, France | Recruiting |
| CHU Grenoble-Alpes - Hopital Michallon | La Tronche, France | Recruiting |
| CHU de Nantes - Hotel-Dieu | Nantes, France | Recruiting |
| CHU de Nimes | Nîmes, France | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06047171